EGFR and hepatocellular carcinoma: Lenvatinib is another multiple TKI targeting epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), VEGFR, and PDGFR.26 Its role in advanced HCC was first reported in a phase II trial in Japan and Korea, showing partial radiological response in 37% of patients and stable disease in 41% of patients after follow-up for over 2 years.27 The landmark REFLECT trial involving head-to-head comparison between lenvatinib and sorafenib was published in 2018.